Biodexa Pharmaceuticals expands Phase 3 clinical trial into Europe and Canada
1 report, 1 independent
Updated Oct 13
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Biodexa Pharmaceuticals PLC announced that it has enrolled 100 patients in its registrational Phase 3 trial of eRapa for Familial Adenomatous Polyposis (FAP). The trial, branded "Serenta," is currently recruiting at 29 clinical sites across the US and five countries in Europe, with two additional sites in Canada expected to start soon.
From manilatimes.net
Why it matters
The enrollment milestone reflects strong recruitment performance for the biopharmaceutical company. The trial protocol includes a pre-specified futility analysis scheduled for early next year and database lock potentially occurring around the end of next year.
From manilatimes.net
Who's involved
- EuropeLocation where the clinical trial is recruiting at five sites
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- European Commission must oversee Biodexa's expanded clinical trialsEuropean Commission must oversee Biodexa's expanded clinical trials in EuropePossible
- Biodexa's Phase 3 trial expansion increases regulatory oversight in BrusselsBiodexa's European clinical trial expansion increases regulatory activity in Brussels.Possible
Keep exploring
The entities involved
-
Europe
terrestrial continent located in north-western Eurasia